Introduction
Leukopenia is observed frequently during HIV-1 infection [1] [2] [3] . For example, evaluation of a large number of incarcerated adults revealed that leukopenia correlated strongly with HIV seropositivity, independent of other variables such as sex with a HIV-positive (HIV+) partner, injection drug use, ethnicity, and presence of sexually transmitted diseases 4, 5 . Interestingly, in these studies the risk for HIV seropositivity associated with leukopenia and a history of sex with a HIV+ partner were similarly high 4 , underscoring that leukopenia is strongly associated with HIV positivity in at-risk individuals and is commonly observed soon after HIV infection. Of note although the sine qua non feature of infection with HIV is progressive immunodeficiency related to CD4 + T cell lymphopenia 6 , CD4 + T cell counts contribute minimally in quantitative terms to the overall WBC count and their decline during the course HIV infection contributes minimally to this observed leukopenia which is mainly attributable to neutropenia.
However, the impact of leukopenia on HIV disease course is largely undefined. Most of the studies that have examined the frequency or HIV disease-influencing effects of cytopenias have employed cross-sectional study designs (e.g., HIV+ vs HIV− 1 or HIV+ neutropenics vs HIV+ non-neutropenics 7 ). These studies have documented that the prevalence of cytopenias is higher in advanced disease. For example, neutropenia ranges from 0.8% to 13.4% when CD4 + counts are below 250 cells/mm 3 and from 13% to 44% in those with AIDS 1, 8 . By contrast there are no prospective studies in natural history cohorts that have examined whether leukopenia impacts on HIV disease course, independent of the known strong relationship between immunodeficiency [reflected by low CD4 + counts or high viral loads (VL)] and either leukopenia or neutropenia 1, 2, 9 .
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To address this, we determined whether leukopenia impacts on the HIV disease course of subjects in a natural history cohort [10] [11] [12] [13] . The large representation of both European Americans (EA) and African Americans (AA) in the study population allowed us to examine whether the impact of leukopenia on disease course differed according to race. This possibility is of particular interest because persons of African ancestry, on average, have significantly lower WBC counts, secondary to lower neutrophil cell counts, than persons of European descent [14] [15] [16] [17] .
In otherwise healthy individuals, low WBC counts in persons of African ancestry are thought to be both genetically determined and benign, as they have not been associated with an increased incidence of bacterial infection 14 . This has resulted in the designation of this condition as "benign ethnic leukopenia or neutropenia" 14, 16, 17 .
In light of the above, we considered whether differences in WBC counts also result in racial differences in HIV disease outcome. Such an analysis could be confounded by social factors (e.g.
access to health care, socioeconomic status). However, our studies were conducted in a wellcharacterized natural history cohort of HIV infection in which several factors that may confound assessment of race-specific differences in disease progression were minimized (e.g., equal access to health care, similar living standards, and minimal loss to follow-up). In our study cohort, the HIV+ AAs had a slight survival advantage compared with HIV+ EAs 10 . This finding was consistent with the survival advantage observed in the HIV-infected AAs in a much larger segment of the same cohort of HIV+ subjects, of which the group that we studied was a subset 12 .
In view of the epidemiological observation that ethnic leukopenia is "benign" in otherwise healthy AAs, a parsimonious explanation for the survival advantage observed in the overall 18, 19 . The -46T C polymorphism is specific to persons of African ancestry 10, [20] [21] [22] , and homozygosity for the -46C allele (-46C/C genotype) abrogates DARC expression on erythrocytes [18] [19] [20] . Because DARC on RBC serves as a receptor for the malarial protozoa Plasmodium vivax 19, 20 , Duffy-null status (DARC -46C/C genotype) on RBC is associated with a selective advantage against this form of malaria. Recent studies revealed two phenotypes associated with the DARC -46C/C genotype that had relevance to both leukopenia and HIV 
METHODS

Study cohort
We used DARC genotyping data, which we reported on recently 10 , derived from HIV-positive subjects from the Department of Defense HIV Natural History Study cohort followed originally at Wilford Hall Medical Center (WHMC) and more recently at the Brooke Army Medical
Center, San Antonio, TX. The studied population is the local (San Antonio) site of a prospective multisite observational cohort from the United States Military's HIV Natural History Study.
Extensive details of the WHMC cohort have been provided elsewhere and all subjects were followed prospectively from the early stages of their infection 10, 11 . The time from diagnosis to entry into the cohort was similar for subjects from different ethnic groups. Fig.1 ), and for this reason we also defined race/ethnicity-specific tertiles for the average WBC counts. To assess the influence of genotypes on survival, we used time to death as the endpoint.
Genotyping
A single-nucleotide polymorphism in DARC T-46C (rs2814778) was genotyped using a TaqMan allelic discrimination assay as described previously 10 .
Statistical analyses
All continuous variables were compared across two groups using the nonparametric MannWhitney test. For survival analyses, we used Kaplan-Meier plots to compare graphically the survival outcomes. Statistical significance of these differences was assessed by log-rank test as well as univariate and multivariate Cox proportional hazards models after testing the assumption of proportionality of hazards using the Schoenfield residuals. To control for the potential effect 
RESULTS
WBC counts and HIV disease course
There was a very high degree of correlation between the initial WBC count at diagnosis (i.e., at entry into cohort) and the average WBC count maintained during HIV disease course (Spearson's rho = 0.7035, p <0.0001, Supplementary Fig. 2 ). The time to death or AIDS in HIVinfected persons was significantly shorter in those with WBC low than those with WBC high (Fig. 1A and data not shown). As the results were similar whether we used AIDS or death as endpoints, the data presented are only for time to death and average WBC counts.
As the average WBC count during infection was strongly positively correlated with the baseline 11, 25 . These analyses revealed that in subjects who presented with low or high baseline CD4 + counts, WBC low was associated with a significantly shorter survival time than in those with WBC high. (Fig. 1B-C ). This suggested that low WBC counts are associated with HIV disease progression independent of the CD4 + T cell count.
Because WBC counts were associated with an accelerated disease course ( Fig. 1A-C) , it could be surmised that a low WBC count merely reflected a more advanced disease stage in those subjects for whom the date of seroconversion was not known. In this instance, the differential survival outcomes observed for WBC low vs WBC high ( Fig. 1A -C) would simply be a reflection of the differences in the disease course of subjects categorized as seroconverters vs seroprevalent individuals. However, this was unlikely to be the case because as compared with those subjects with WBC high , those with WBC low had a faster disease course regardless of whether they were categorized as seroconverting or seroprevalent, or whether the baseline CD4 + count was low or high ( Fig. 1D-I ).
To test the robustness of these observations, we conducted multivariate Cox proportional hazards regression analyses and found that WBC low was a strong predictor of shorter survival times, independent of baseline CD4 + counts and steady-state VL that in this study population are strong predictors of disease progression 11, 25 (Table 1) . For example, in the seroconverting subjects, the hazard ratio for time to death for those with WBC low was 1.80 (Table 1) . Collectively, these findings ( Fig. 1 and Table 1 ) indicated that a low WBC count is an independent determinant of an accelerated HIV disease course.
Race and leukopenia and HIV infection
As the prevalence of leukopenia is higher in persons of African Fig. 3A ). The prevalence (%) of leukopenia at time of diagnosis was significantly higher in HIV+ AAs (28%) than in EAs (15%, P=0.0047) or HIV+ persons of other ethnicities (13%, P=1.7x10 -10 ) that were represented in the study cohort (Fig. 2B ). These data indicated that ethnic leukopenia present in healthy AAs was also present in the setting of HIV infection.
Race and leukopenia and HIV disease
As ethnic leukopenia is associated with a benign phenotype in HIV-uninfected AAs, we investigated whether this benign phenotype was reflected in a more benign HIV disease course in ) subjects (Fig. 3) .
We undertook further analyses and found that leukopenic EAs had a survival disadvantage compared to leukopenic AAs leukopenia whether leukopenia was defined by contemporary (<4,000 cells/mm 3 ) versus population-specific cut-offs observed in the study cohort (see Supplementary Fig. 4 ).
Duffy status, race and leukopenia
The aforementioned data suggested that ethnic leukopenia existed in HIV+ AAs, and that leukopenic HIV+ AAs had a more benign disease course relative to leukopenic EAs. To investigate if there was a genetic basis for this, we determined whether there was any relationship between the aforementioned findings and the recent observation demonstrating that DARC -46C/C is a strong genetic basis for benign ethnic leukopenia, attributable to neutropenia, in HIV-negative subjects 21, 22 .
In our study population, DARC -46C/C was present nearly exclusively in AAs (69.1%) compared with EA (0.2%) 10 .
Among the hematological parameters available for assessment, DARC T-46C
For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From genotype (T/T, T/C, C/C), but not race was a strong determinant of the variability in the WBC counts during disease (Table 2 ) and at entry into the cohort (P=3.9x10 -12 ). Furthermore, among HIV+ AAs, leukopenia at time of diagnosis was three times more prevalent in those with -46C/C (36%) than those with DARC -46 C/T or -46 T/T (11.5%; Fig. 2C ). Concordantly, WBC counts were lower in those AAs bearing DARC -46C/C than other DARC genotypes ( Fig. 2D and Supplementary Fig. 3B ). Taken together ( Table 2 and Fig. 2 ), our results in HIV+ patients are concordant with those recent findings that the DARC genotype and not race was a strong predictor of variability in WBC/neutrophil counts in non-HIV cohorts 21, 22 .
DARC-46C/C, leukopenia and disease course
Consistent with our previous data 10 in the overall study population and, therein the seroconverting and seroprevalent populations, there was a trend towards a survival advantage for HIV+ AAs with -46 C/C compared to HIV+ EAs , or AAs with DARC -46 C/T or T/T (Fig. 4A-C ). However, the survival advantage associated with -46C/C was highly dependent on WBC counts as this association was greatly magnified in subjects with WBC low (Fig. 4D-F ) and muted in those with WBC high (Fig. 4G-I ).
To investigate whether the accentuation of the DARC genotype-phenotype associations with leukopenia were meaningful and not artifactual, we determined whether disease course differed according to DARC genotype in subjects categorized according to their baseline CD4 + T cell count (< or > 350 cells/mm 3 ) (Supplementary Fig. 5 ). These analyses revealed that the diseaseinfluencing phenotype associated with DARC -46C/C differed substantially according to the WBC (Fig. 4) but not CD4 + counts (Supplementary Fig. 5 ).
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We further explored the relationships between DARC genotype, leukopenia, and HIV disease course in HIV+ AAs using univariate, multivariate and other statistical approaches. Univariate models revealed that among those with WBC low , the hazard ratio for survival associated with DARC -46C/C was one-third (RH=0.33) of that associated with DARC -46 C/T or T/T (RH=1; Table 3 ). In a multivariate model stratified for seroconversion status and receipt of antiretroviral therapy, DARC -46C/C was associated with a nearly 80% (RH=0.20) lower risk of progressive disease, independent of other covariates that are strong predictors of disease progression 11 as well as a genetic parameter designated as admixture score 10 ( Table 3) . Substantiating this, in stepwise Cox regression modeling, the DARC -46C/C genotype was retained as a significant predictor of disease progression but only in subjects with a low WBC count (Table 3) . In these analyses, an association between DARC -46C/C and survival was not observed in subjects with WBC high (Table 3 ). These data indicate that DARC -46C/C is an independent determinant of disease course, but mainly in those with a low WBC count.
DARC -46C/C, magnitude of leukopenia and disease course
The aforementioned genotype-phenotype analyses were conducted with a fixed WBC cut-off of 4,000 cells/mm 3 . However, it was plausible that the association between DARC genotype with disease progression was quantitatively dependent on the magnitude of leukopenia. We therefore evaluated the hazard ratio for survival associated with DARC -46C/C in HIV+ AAs subjects at different thresholds of average WBC counts (Fig. 5 ). This analysis revealed that with each stepwise decrement in the average WBC count, the hazard ratios for time to death associated with DARC -46C/C progressively improved (Fig. 5 ). This suggested that it was the interaction
between DARC genotype and WBC counts that actually influenced HIV disease course. This inference was consistent with the results of the interactive logistic regression model that we used to investigate whether (i) leukopenia, (ii) DARC -46C/C, and (iii) the interaction between leukopenia and DARC genotype were each associated with independent disease-influencing effects (Fig. 5 ). In this model, among HIV+ AAs, each 500 cell decrement in the average WBC count during disease was associated with a significantly increased risk of progressive HIV disease (RH=1.65; P=1.8x10 -6 ; Fig. 5, inset) . Notably, this hazard ratio of 1.65 is consistent with that observed for leukopenic AAs ( Our previous data showed that DARC -46C/C associated with a slow HIV disease course in the overall AA study population 10 . We now show that this association is evident mainly in those AAs who maintained a low WBC count during disease, suggesting that the genotype-phenotype relationships for the DARC-null state are highly dependent on the cellular milieu. These findings may also help explain the observation that neutropenia, which is found commonly in HIV- analyses showing that among HIV+ AAs it was the interaction between DARC -46C/C and WBC counts, and not DARC genotype alone that was associated with a survival advantage (Fig. 5,   inset ). This dependence of DARC genotype on WBC counts for full expression of its phenotypic
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A second possibility is that DARC -46C/C may be merely a surrogate for other unknown genotypes which influence HIV disease course in the setting of leukopenia. Because WBC counts are a genetically-related phenotype, it follows that subjects with leukopenia may be enriched for polymorphisms in other genes that confer a low WBC count trait. In this setting the cellular milieu defined by genetically-determined leukocyte count profiles and/or genes that track with leukopenia (which may include DARC -46C/C) may serve as a modifier of HIV disease. Although we cannot exclude this possibility, we outline below several observations that together favor a role for DARC in HIV pathogenesis.
Why does the DARC -46C/C genotype specifically associate with a survival advantage in those HIV-infected AAs who have a low WBC count? Indeed, that leukopenia could be 'good' for a patient appears on the surface to be counter intuitive. We speculate that what we have observed in the context of HIV infection may reflect an evolutionarily adaptive mechanism to limit both inflammatory response and cell entry, to an ancestral pathogen such as P. vivax. The DARC locus shows complex genetic signatures of positive natural selection 26, 27 , and it has been suggested that the -46C allele has arisen under the selective pressure of an ancestral form of malaria that also used DARC, but was more lethal than P. vivax, which is generally not associated with mortality and is no longer very common in Africa 20 . Interestingly, neutropenia is commonly observed during malaria and is more common in infection with P. vivax than P. falciparum 28, 29 , and there is clinical and experimental evidence that neutrophils contribute to the adverse outcomes [30] [31] [32] [33] [34] . Furthermore, a genome-wide analysis of the host response to malaria also implicates neutrophil-mediated pathways in underlying malarial pathogenesis 35 .
Hence, one possibility is that the protection against neutrophil-mediated inflammation during infection by a lethal ancestral form of malaria may have also promoted the selection of the Duffy-null trait.
Studies suggest that ethnic leukopenia/neutropenia may be related to a reduced ability to mobilize neutrophils from the marginated granulocyte pool 36 . Supporting this, studies in mouse models show that DARC expression on both RBC and endothelial cells influences neutrophil migration 37, 38 . Also, DARC -46C/C may associate with impaired hematopoiesis because some of the chemokines that bind to DARC (e.g. GROα 39 ) regulate many hematopoietic responses, including survival, proliferation, migration, and homing 40 . Supporting this possibility, healthy subjects of African ancestry have reduced numbers of bone marrow progenitor cells than Caucasians 41 . Although the precise mechanism underlying ethnic leukopenia is unknown, given the importance of neutrophils in inflammation, the reduced numbers of circulating neutrophils associated with DARC -46C/C may lead to dampened inflammatory responses, and this may explain in part the "benign" nature of ethnic leukopenia. In contrast, the HIV-associated leukopenia/neutropenia observed in EAs or AAs who bear at least one DARC -46T allele is associated with a less favorable outcome possibly because this leukopenia occurs within the context of the Duffy-positive state and hence originates from a different mechanism which is not associated with a "benign" leukopenia.
Additional data suggest a link between DARC -46C/C and inflammatory responses relevant to
HIV pathogenesis. Studies demonstrate a key role for circulating lipopolysaccharide (LPS), a marker of microbial translocation, and inflammation in the pathogenesis of HIV infection, especially acute infection 42 . In this respect it is notable that following administration of LPS (endotoxin) to healthy individuals, compared with Duffy-positive Caucasians, Duffy-null individuals of African descent had significantly lower levels of total blood chemokine levels (derived from plasma levels, red blood cell-and neutrophil-associated MCP-1, GROα, and IL-8, ligands of DARC) 24 . This may have relevance to HIV pathogenesis because prior studies had found that plasma levels of MCP-1, a chemokine that associates with higher HIV viral load in vivo and increased viral replication in vitro 43 , are lower in Duffy-null subjects 44 . Notably, IL-8 is a potent chemoattractant of neutrophils and application of glycerol monolaurate, an inhibitor of IL-8, protected these animals from infection 48 .
There may be additional mechanisms by which DARC influences HIV pathogenesis. In a previous study 10 , we found that in addition to binding to HIV-suppressive chemokines, HIV also binds to erythrocyte DARC in vitro, and that RBC-bound HIV can be displaced by chemokines and transferred in trans to CD4+ T cells 10 For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From Tables   Table 1. Association of low WBC counts during disease with rapid rate of HIV disease progression, independent of baseline CD4 + T cell count and steady-state viral load (VL) in the entire study population (all subjects) or subjects categorized as seroconverters or seroprevalent.
All Subjects Seroconverters Seroprevalent
Average WBC count <4000 Results are from full multivariate Cox proportional hazards models showing relative hazards (95% CI) for time-to-death and P value. T cell count (cCD4), a parameter that reflects the changes in CD4 + counts over disease course and is a very strong predictor of disease progression 11 ; steady-state viral load; and an admixture score derived from 11 genetic markers that was highly predictive of self reported ethnicity (>98% accuracy) 10 and was also strongly correlated with the degree of admixture as assessed by the first principal component (obtained by EIGENSOFT program) of 96 ancestry informative markers 49 . Both full model and final step-wise model have been adjusted for seroconversion and receipt of antiretroviral therapy, as defined previously 11 . Results depicted are relative hazards (95% CI) for time-to-death and P value. RH =1 represents those with DARC -46C/T or T/T. For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From
